| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2009;40:1858.)
© 2009 American Heart Association, Inc.
Original Contributions |
From the Department of Neurosurgery (M.O., Y.H., R.F.K., L.B.M., G.X.) and the Stroke Program (R.F.K., L.B.M., G.X.), University of Michigan, Ann Arbor, Mich.
Correspondence to Guohua Xi, MD, R5018, BSRB, University of Michigan, Ann Arbor, MI 48109-2200. E-mail guohuaxi{at}umich.edu
Background and Purpose— Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats. In the present study, we investigated whether DFX is effective on brain injury after ICH in aged rats and examined dose dependency.
Methods— Male Fischer 344 rats (18 months old) had an intracaudate injection of 100 µL autologous whole blood and were treated with different doses of DFX (10, 50, and 100 mg/kg) or vehicle 2 and 6 hours post-ICH and then every 12 hours up to 7 days. Rats were euthanized at Day 3 for brain edema determination and Day 56 for brain atrophy measurement. Behavioral tests were performed during the experiments.
Results— All 3 doses of DFX attenuated perihematomal brain edema at 3 days (eg, at dose 50 mg/kg, 80.4±0.5 versus 81.6±0.9% in the vehicle-treated group, P<0.01). Fifty and 100 mg/kg DFX also reduced ICH-induced ventricle enlargement, caudate atrophy, and ICH-induced neurological deficits in aged rats. However, although 10 mg/kg DFX reduced ventricle enlargement and forelimb-placing deficits, it did not reduce caudate atrophy and corner turn deficits.
Conclusions— These results indicate that DFX can reduce ICH-induced brain injury in aged as well as young rats and that a dose >10 mg/kg is the optimal dose of DFX in this model.
Key Words: brain atrophy cerebral hemorrhage deferoxamine iron
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |